Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia, a condition that affects more than twenty three million men worldwide. Urologix' products include the CoolWave, Targis and Prostatron control units and the Cooled ThermoCath, Targis and Prostaprobe catheter families. Additionally, Urologix is currently developing CoolMax, its next generation microwave catheter for in-office benign prostatic hyperplasia treatment. All of Urologix' products utilize Cooled ThermoTherapy targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort and provide safe, effective, lasting relief of the symptoms of benign prostatic hyperplasia.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | -- |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | -- |
| Quick Ratio (Most Recent Fiscal Quarter) | -- |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | -- |
| Free Float | -- |
| Market Capitalization | -- |
| Average Volume (Last 20 Days) | 125.00 |
| Beta (Past 60 Months) | -38.76 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |